Peptide Calculator
Retatrutide calculator
Pre-filled with common Retatrutide vial sizes. Adjust any value to match your specific vial and dose.
About Retatrutide
Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. Phase II trials reported average weight loss of approximately 24% at the highest dose over 48 weeks. Phase III trials are ongoing as of 2026. Retatrutide is not FDA-approved and is not legally available outside of clinical trials.
Common Retatrutide vial sizes
| Vial size | BAC water | Concentration |
|---|---|---|
| 5mg | 2mL | 2,500 mcg/mL |
| 10mg | 2mL | 5,000 mcg/mL |
Frequently asked questions
Is retatrutide available to the public?
Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or investigational frameworks, but this carries significant legal and safety risk.
When might retatrutide receive FDA approval?
Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.
What concentration does a 5mg retatrutide vial give with 2mL BAC water?
Reconstituting a 5mg vial with 2mL of BAC water gives a concentration of 2,500 mcg/mL. Use the calculator above to find the draw volume for a specific dose.